Development of an indirect competitive ELISA based on immunomagnetic beads’ clean-up for detection of maduramicin in three chicken tissues

<p>An indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) based on immunomagnetic beads' (IMBs) clean-up was developed for detection of the residues of maduramicin (MD) in different chicken tissues. IMBs coated with a specific monoclonal antibody (MAb) against MD named MAb 2D6 were applied to enrich the residues of MD in chicken tissues. The specificities of these IMBs were well maintained and the reversibility remained at more than 73% of the original capability after being used for three times. After elution, enriched MD was detected by a conventional ic-ELISA. The limits of detection of MD were 72, 74 and 173 μg/kg in chicken muscle, skin and fat, and liver, respectively. Recoveries ranged from 80.0% to 115.8% with coefficients of variation being less than 11.3%. These results indicated that a rapid, robust clean-up of IMBs combining ELISA provides a simple, time-saving and environmentally friendly method to detect MD in chicken tissues.</p

Additional file 1 of Circulating exosomal mir-16-2-3p is associated with coronary microvascular dysfunction in diabetes through regulating the fatty acid degradation of endothelial cells

Supplementary Material

Selenylsulfide Bond-Launched Reduction-Responsive Superparamagnetic Nanogel Combined of Acid-Responsiveness for Achievement of Efficient Therapy with Low Side Effect

With the objective to achieve in-between reduction-responsive drug release, selenylsulfide bond was first explored as a reduction cleavable linkage, compared with the most commonly employed disulfide and diselenide bonds. The reductive nanogel, with a combination of superparamagnetic and acid responsiveness, was fabricated. The expected release profiles were testified. Cytotoxicity assays illustrated the remarkable inhibition to the growth of HeLa cells, in contrast, high tolerance to L02 cells. In vivo investigation exhibited the obvious shrinkage in tumor but a healthy appearance. Hematoxylin-eosin staining and histological examination revealed the lower toxicity. The complex nanogels would have appeared highly promising in cancer therapy

Transdermal Drug Delivery System: Current Status and Clinical Application of Microneedles

As a new type of transdermal drug delivery system (TDDS), microneedles have garnered significant attention for their noninvasiveness, portability, controllable drug administration, and wide-ranging loading capacity. While initially designed for transdermal administration via the stratum corneum for minimizing adverse reactions associated with systemic administration and enhancing patient compliance, microneedles have recently found applications in a multitude of medical contexts. Hence, their potential in medical applications transcends mere drug delivery. Recent reviews on microneedles have extensively covered various aspects, including needle types, materials, and manufacturing methods, as well as their applications in treating skin diseases. This review aims to provide a comprehensive overview of the diverse designs and applications of microneedles from different new perspectives, which encompass traditional integrated microneedles as well as more intelligent and structurally optimized ones in nowadays. Additionally, this review offers a comprehensive analysis of the material properties utilized in microneedles for different applications, including nondegradable materials and degradable materials. Furthermore, the review presents the wide-ranging applications of these microneedles in different medical scenarios such as regeneration and repair, disease treatment, monitoring, and prevention. Moreover, the discussion of the article highlights the future clinical applications of microneedles and the necessary efforts required to achieve their widespread adoption. This review serves as a valuable reference for bridging the gap between the laboratory setting and the clinical practice in terms of using microneedles in medical scenarios